Antimetabolic cooperativity with the clinically approved l-asparaginase and tyrosine kinase inhibitors to eradicate CML stem cells

• Váldodahkkit: Anne Trinh (Dahkki), Raeeka Khamari (Dahkki), Quentin Fovez (Dahkki), François-Xavier Mahon (Dahkki), Béatrice Turcq (Dahkki), Didier Bouscary (Dahkki), Patrice Maboudou (Dahkki), Marie Joncquel (Dahkki), Valérie Coiteux (Dahkki), Nicolas Germain (Dahkki), William Laine (Dahkki), Salim Dekiouk (Dahkki), Sandrine Jean-Pierre (Dahkki), Veronique Maguer-Satta (Dahkki), Bart Ghesquiere (Dahkki), Thierry Idziorek (Dahkki), Bruno Quesnel (Dahkki), Jerome Kluza (Dahkki), Philippe Marchetti (Dahkki)
• Materiálatiipa: Girji
• Almmustuhtton: Elsevier, 2022-01-01T00:00:00Z.
• Fáttát: article
• Liŋkkat: Connect to this object online.

Objective: Long-term treatment with tyrosine kinase inhibitors (TKI) represents an effective cure for chronic myeloid leukemia (CML) patients and discontinuation of TKI therapy is now proposed to patient with deep molecular responses. However, evidence demonstrating that TKI are unable to fully erad...